Top

Published in:

01-06-2013

Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial

Authors: A. Y. F. Chung, L. L. P. J. Ooi, D. Machin, S. B. Tan, B. K. P. Goh, J. S. Wong, Y. M. Chen, P. C. N. Li, M. Gandhi, C. H. Thng, S. W. K. Yu, B. S. Tan, R. H. G. Lo, A. M. M. Htoo, K. H. Tay, F. X. Sundram, A. S. W. Goh, S. P. Chew, K. H. Liau, P. K. H. Chow, K. H. Tay, Y. M. Tan, P. C. Cheow, C. K. Ho, K. C. Soo

Published in: World Journal of Surgery | Issue 6/2013

Abstract

Background

The purpose of the present study was to determine whether intrahepatic injection of ¹³¹I-lipiodol (Lipiodol) is effective against recurrence of surgically resected hepatocellular carcinoma (HCC).

Methods

From June 2001 through March 2007, this nationwide multi-center prospective randomized controlled trial enrolled 103 patients 4–6 weeks after curative resection of HCC with complete recovery (52: Lipiodol, 51: Control). Follow-up was every 3 months for 1 year, then every 6 months. Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively, both of which were evaluated by the Kaplan–Meier technique and summarized by the hazard ratio (HR). The design was based on information obtained from a similar trial that had been conducted in Hong Kong.

Results

The Lipiodol group showed a small, and nonsignificant, improvement over control in RFS (HR = 0.75; 95 % confidence interval [95 % CI] 0.46–1.23; p = 0.25) and OS (HR = 0.88; 95 % CI 0.51–1.51; p = 0.64). Only two serious adverse events were reported, both with hypothyroidism caused by ¹³¹I-lipiodol and hepatic artery dissection during angiography.

Conclusions

The randomized trial provides insufficient evidence to recommend the routine use of ¹³¹I-lipiodol in these patients.

Parkin DM, Whelan SL, Ferlay J et al (2002) Cancer incidence in five continents, vol VIII. IARC Scientific, Lyon publication no. 155

Parfitt JR, Marotta P, Alghamdi M et al (2007) Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transplant 13:543–551CrossRef

Shah A, Cleary SP, Wei AC et al (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141:330–339PubMedCrossRef

Tanaka S, Noguchi N, Ochiai T et al (2007) Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg 204:1–6PubMedCrossRef

Lau WY (2002) Management of hepatocellular carcinoma. J R Coll Surg Edinb 47:389–399PubMed

Matsuda Y, Ito I, Oguchi Y et al (1993) Rationale of surgical management for recurrent hepatocellular carcinoma. Ann Surg 217:28–34PubMedCrossRef

Schwartz JD, Schwartz M, Mandeli J et al (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomized trials. Lancet Oncol 3:593–603PubMedCrossRef

Samuel M, Chow PK, Chan Shih-Yen E et al. (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (1):CD001199

Lau WY, Leung TW, Ho SK et al (1999) Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 353:797–801PubMedCrossRef

10.

Pocock S, White I (1999) Trials stopped early: too good to be true? Lancet 353:943–944PubMedCrossRef

11.

Machin D, Campbell MJ, Fayers PM et al (1997) Statistical tables for the design of clinical studies. Blackwell Scientific, Oxford

12.

Madsen MT, Park CH, Thakur ML (1988) Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038–1044PubMed

13.

Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 1). Society of Nuclear Medicine, Reston

14.

Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 2). Society of Nuclear Medicine, Reston

15.

Snyder WS, Ford MR, Warner GG et al (1975) MIRD pamphlet #11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs (part 3). Society of Nuclear Medicine, Reston

16.

Lau WY, Lai EC, Leung TW et al (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma, a prospective randomized trial—update on 5-year and 10-year survival. Ann Surg 247:43–48PubMedCrossRef

17.

Boucher E, Corbinais S, Rolland Y et al (2003) Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237–1241PubMedCrossRef

18.

Tabone M, Vigano L, Ferrero A et al (2007) Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 33:61–66PubMedCrossRef

19.

Poon RT, Fan ST, Ng IO et al (2000) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231:544–551PubMedCrossRef

20.

Poon RT, Fan ST, Wong J (2000) Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef

21.

Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and slow phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207PubMedCrossRef

22.

Poon RT, Fan ST, Ng IO et al (2000) Different risk factors and prognosis for early and slow intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500–507PubMedCrossRef

Title: Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial
Authors: A. Y. F. Chung
L. L. P. J. Ooi
D. Machin
S. B. Tan
B. K. P. Goh
J. S. Wong
Y. M. Chen
P. C. N. Li
M. Gandhi
C. H. Thng
S. W. K. Yu
B. S. Tan
R. H. G. Lo
A. M. M. Htoo
K. H. Tay
F. X. Sundram
A. S. W. Goh
S. P. Chew
K. H. Liau
P. K. H. Chow
K. H. Tay
Y. M. Tan
P. C. Cheow
C. K. Ho
K. C. Soo
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 6/2013
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-013-1970-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Impact of Skin Grafting of Venous Leg Ulcers on Functional Status and Pain

Early and Late Presentations of Graft Arterial Pseudoaneurysm Following Pancreatic Transplantation

What Is Riskier for the Patient with an Asymptomatic Large Hepatic Hemangioma: Observation or the Surgeon?

Pancreatic Anastomotic Leakage after Pancreaticoduodenectomy. Risk factors, Clinical predictors, and Management (Single Center Experience)

Aggressive Treatment for Hepatic Metastases from Breast Cancer: Results from a Single Center

Hilar Cholangiocarcinoma: Preoperative Liver Optimization with Multidisciplinary Approach. Toward a Better Outcome